Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley

Trevi Therapeutics (NASDAQ:TRVI) had its target price dropped by stock analysts at Morgan Stanley from $19.00 to $18.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price target suggests a potential upside of 67.44% from the stock’s current price.

A number of other equities research analysts have also commented on TRVI. D. Boral Capital restated a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Wednesday. Leerink Partners upped their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Finally, Needham & Company LLC boosted their price target on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $21.20.

Trevi Therapeutics Stock Performance

NASDAQ TRVI traded down $0.44 during trading hours on Wednesday, reaching $10.75. 570,998 shares of the company’s stock were exchanged, compared to its average volume of 1,364,025. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -29.04 and a beta of 0.94. The company’s 50-day moving average is $11.17 and its two-hundred day moving average is $10.93. Trevi Therapeutics has a one year low of $4.85 and a one year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. Research analysts predict that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TRVI. China Universal Asset Management Co. Ltd. boosted its stake in shares of Trevi Therapeutics by 4.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock valued at $195,000 after purchasing an additional 911 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in Trevi Therapeutics by 20.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock worth $70,000 after purchasing an additional 1,300 shares in the last quarter. Kennedy Capital Management LLC increased its position in Trevi Therapeutics by 2.4% during the 4th quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock worth $704,000 after purchasing an additional 1,336 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Trevi Therapeutics by 32.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares during the last quarter. Finally, BIT Capital GmbH lifted its stake in Trevi Therapeutics by 32.0% in the 3rd quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock valued at $62,000 after purchasing an additional 1,633 shares during the last quarter. Institutional investors own 95.76% of the company’s stock.

Trending Headlines about Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: FDA alignment on Phase 3 program — Trevi announced end-of-Phase 2 alignment with the FDA and plans two pivotal Phase 3 trials for IPF-related chronic cough, materially reducing regulatory uncertainty and increasing the potential pathway to approval and commercial value. Article Title
• Positive Sentiment: Corporate update / press release confirming FDA alignment and business plan — Company release summarizes Q4 results and the FDA outcome, framing the Phase 3 strategy and next milestones (trial design/timelines). This provides clearer catalysts for 2026–2027 value realization. Article Title
• Positive Sentiment: Analyst price-target increases — Needham raised its price target from $22 to $24 (buy) and D. Boral Capital reaffirmed a buy with a $19 target. Both lifts signal stronger sell-side conviction and imply substantial upside vs. current levels, which can support sentiment and buying interest. Article Title
• Positive Sentiment: Quarterly results: slight EPS beat — Trevi reported Q4 GAAP EPS of ($0.06) vs. consensus ($0.10), a modest beat that suggests controlled spend or better-than-expected execution; however EPS remains negative while the company advances clinical programs. Article Title
• Neutral Sentiment: Earnings call transcript and highlights — Management commentary (Q4 call transcript and write-ups) provides detail on Phase 3 design and timing; useful for modeling but no new surprises beyond FDA alignment. Article Title Article Title
• Neutral Sentiment: Valuation write-up — Recent articles examine Trevi’s valuation post-FDA green light; useful context for investors deciding whether current upside implied by analysts is justified but not an immediate catalyst. Article Title

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.